SCHEMBL24025490

SCHEMBL24025490

COC(=O)CC1CCN(S(=O)(=O)c2ccc(F)nc2)CC1

nearest known ligand 0.46

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.46
▸ KDM4E B2RXH2 3/20 0.46
▸ TSHR P16473 4/20 0.45
▸ HSD17B10 Q99714 2/20 0.45
▸ HPGD P15428 1/20 0.45
▸ MAPT P10636 3/20 0.44
▸ CCR6 P51684 2/20 0.44
▸ PKM P14618 2/20 0.44
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ LMNA P02545 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ USP5 P45974 1/20 0.42
▸ USP2 O75604 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24025547 0.86 ALDH1A1 (0.56) ALDH1A1KDM4EMAPTCCR6PKM
SCHEMBL23779174 0.83 PKM (0.64) ALDH1A1TSHRHPGDPKMKMT2A
SCHEMBL23779154 0.79 AOC2 (0.50) —
SCHEMBL30885687 0.79 AOC2 (0.50) —
SCHEMBL23779157 0.79 AOC2 (0.50) —
SCHEMBL24025494 0.79 AOC2 (0.50) —
SCHEMBL24057502 0.79 EPHX2 (0.50) ALDH1A1MAPTMEN1KMT2ALMNA
SCHEMBL26345567 0.78 AOC2 (0.40) ALDH1A1KDM4ETSHRMAPTCCR6
SCHEMBL24025637 0.75 KDM4E (0.44) ALDH1A1KDM4ETSHRHSD17B10HPGD
SCHEMBL24025395 0.74 KDM4E (0.44) ALDH1A1KDM4ETSHRHSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3873600-B9 PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF BOEHRINGER INGELHEIM INT (DE) 2024-02-14 — — EP disclosed
EP-3873599-B1 PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF BOEHRINGER INGELHEIM INT (DE) 2023-09-27 — — EP disclosed
EP-3873600-B1 PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF BOEHRINGER INGELHEIM INT (DE) 2023-09-20 — — EP disclosed
US-20210361637-A1 PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2021-11-25 — — US disclosed
US-20210353608-A1 PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2021-11-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210353608-A1 PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF ARSA, SULT1A1, SULT2A1 ALDH1A1 455/4885KDM4E 3461/4885TSHR 1733/4885
US-20210361637-A1 PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF ARSA, SULT1A1, SULT2A1 ALDH1A1 455/4885KDM4E 3461/4885TSHR 1733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback